A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs

Core Insights - ImmunityBio (IBRX) reported a 3Q25 GAAP EPS loss of -$0.07, beating estimates by approximately $0.04 [1] - Revenue for the quarter was $32.06 million, representing a significant year-over-year increase of 425% and slightly exceeding expectations by $0.18 million [1] Company Performance - The company achieved a notable revenue growth of 425% year-over-year, indicating strong operational performance and market demand for its products [1] - The EPS loss of -$0.07 suggests that while the company is still in a loss position, it is performing better than analysts had anticipated [1]